Cargando…
A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer
A novel paradigm in tumor biology suggests that non-small-cell lung cancer (NSCLC) growth is driven by lung cancer stem cell (LCSC) like cells, but t here are still not any effective strategies to remove LCSCs. The bispecific antibody (BsAb) is a novel antibody, which can target two different antige...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542762/ https://www.ncbi.nlm.nih.gov/pubmed/29187584 http://dx.doi.org/10.1042/BSR20171278 |
_version_ | 1783422975891996672 |
---|---|
author | Li, Jian-feng Niu, Yuan-yuan Xing, Yan-li Liu, Feng |
author_facet | Li, Jian-feng Niu, Yuan-yuan Xing, Yan-li Liu, Feng |
author_sort | Li, Jian-feng |
collection | PubMed |
description | A novel paradigm in tumor biology suggests that non-small-cell lung cancer (NSCLC) growth is driven by lung cancer stem cell (LCSC) like cells, but t here are still not any effective strategies to remove LCSCs. The bispecific antibody (BsAb) is a novel antibody, which can target two different antigens and mediate specific killing effects by selectively redirecting effector cells to the target cells. Here, we designed and synthesized a new BsAb, BsAb-5, that can target cellular mesenchymal-to-epithelial transition factor (c-MET) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in CD166(+) LCSCs with high affinity and specificity, for the first time. We showed that BsAb-5 could inhibit hepatocyte growth factor (HGF) mediated tumor development, including proliferation, migration, and apoptosis, serving as an inhibitory c-MET antibody. Moreover, we demonstrated that mechanisms responsible for BsAb-5 in CD166(+) LCSCs included inducing c-MET degradation and inhibition of HGF-stimulated c-MET-Notch pathway by using AdHGF infection, nuclei location, and Western blot assays. In vivo, xenograft analysis revealed that mice on BsAb-5 group showed significantly reduced tumor volume. At the meantime, the observed antitumor effects of BsAb-5 were dependent on considerably suppressing T-regulatory cells (T(regs)) and up-regulating effector T cells. On the basis of these results, we have identified a potential BsAb drug, which can effectively target c-MET and CTLA-4 in CD166(+) LCSCs for the treatment of human NSCLC. |
format | Online Article Text |
id | pubmed-6542762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65427622019-06-07 A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer Li, Jian-feng Niu, Yuan-yuan Xing, Yan-li Liu, Feng Biosci Rep Research Articles A novel paradigm in tumor biology suggests that non-small-cell lung cancer (NSCLC) growth is driven by lung cancer stem cell (LCSC) like cells, but t here are still not any effective strategies to remove LCSCs. The bispecific antibody (BsAb) is a novel antibody, which can target two different antigens and mediate specific killing effects by selectively redirecting effector cells to the target cells. Here, we designed and synthesized a new BsAb, BsAb-5, that can target cellular mesenchymal-to-epithelial transition factor (c-MET) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) in CD166(+) LCSCs with high affinity and specificity, for the first time. We showed that BsAb-5 could inhibit hepatocyte growth factor (HGF) mediated tumor development, including proliferation, migration, and apoptosis, serving as an inhibitory c-MET antibody. Moreover, we demonstrated that mechanisms responsible for BsAb-5 in CD166(+) LCSCs included inducing c-MET degradation and inhibition of HGF-stimulated c-MET-Notch pathway by using AdHGF infection, nuclei location, and Western blot assays. In vivo, xenograft analysis revealed that mice on BsAb-5 group showed significantly reduced tumor volume. At the meantime, the observed antitumor effects of BsAb-5 were dependent on considerably suppressing T-regulatory cells (T(regs)) and up-regulating effector T cells. On the basis of these results, we have identified a potential BsAb drug, which can effectively target c-MET and CTLA-4 in CD166(+) LCSCs for the treatment of human NSCLC. Portland Press Ltd. 2019-05-31 /pmc/articles/PMC6542762/ /pubmed/29187584 http://dx.doi.org/10.1042/BSR20171278 Text en © 2019 The Author(s). http://creativecommons.org/licenses/by/4.0/This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY) (http://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Articles Li, Jian-feng Niu, Yuan-yuan Xing, Yan-li Liu, Feng A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
title | A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
title_full | A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
title_fullStr | A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
title_full_unstemmed | A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
title_short | A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
title_sort | novel bispecific c-met/ctla-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542762/ https://www.ncbi.nlm.nih.gov/pubmed/29187584 http://dx.doi.org/10.1042/BSR20171278 |
work_keys_str_mv | AT lijianfeng anovelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT niuyuanyuan anovelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT xingyanli anovelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT liufeng anovelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT lijianfeng novelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT niuyuanyuan novelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT xingyanli novelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer AT liufeng novelbispecificcmetctla4antibodytargettinglungcancerstemcelllikecellswiththerapeuticpotentialinhumannonsmallcelllungcancer |